



SUBJECT: EVALUATION ADVISORY COMMITTEE CHAIR REPORT

Category: For Information

Section A: Introduction

• This report provides the Board with an overview of the activities of the Evaluation Advisory Committee (EAC) since the Committee Chair last reported to the Board in December 2020.

- The EAC met virtually on 14 and 15 April to approve the multi-year evaluation workplan for Gavi 5.0; provide guidance on the Evaluation Operational Guidelines (EOGs); and discuss approaches adopted in the evaluation sector to adapt evaluation methods in response to COVID-19 and in fragile and conflict contexts.
 - The EAC acknowledged that the 5.0 multi-year evaluation workplan is comprehensive, covering the key strategic areas for centralised evaluation.
 - The EAC noted the interconnectivities between the 5.0 centralised evaluations, particularly around the zero-dose approach with fragile and conflict settings and impact of COVID-19 on Expanded Programme on Immunization (EPI) programmes (and the lack of data in these contexts).
 - The EAC provided feedback on the proposed evaluation questions and emphasised the importance of sharing findings between evaluations in a time-efficient manner.
- During a closed session on 14 April, the EAC noted with satisfaction the reaffirmation by the Gavi leadership of the importance of the EAC in supporting the independence of Gavi's evaluations, and in guiding mitigation actions in the event of perceived potential risks to evaluation independence.
- The EAC also emphasised the need to further strengthen the linkages with the Programme and Policy Committee (PPC) and communication channels with the Board.
- The EAC did record some concerns regarding key shifts in the Evaluation Operational Guidelines (EOGs) and agreed to provide written comments by consensus following the EAC meeting. A consensus statement was submitted by the EAC to the Gavi Secretariat on 30 April 2021, as a constructive roadmap for the way forward, and this will be provided to the incoming Chair for consideration.



- The EAC reviewed and provided feedback on the terms of reference for the COVAX Facility and COVAX AMC Evaluability, Evaluation Design and Baseline Study and provided quality assurance on the draft final report for the Supply and Procurement Strategy Evaluation¹. The EAC assessment of the Supply and Procurement Strategy Evaluation noted that the evaluation fully met or exceeded Gavi quality standards.
- The EAC Chair report is attached in the form of a presentation as Annex A and the EAC recommendations to the Board are attached as Annex B.

Annexes

Annex A: EAC Chair report

Annex B: EAC recommendations to Gavi Alliance Board

2

¹ https://www.gavi.org/programmes-impact/our-impact/evaluation-studies/gavi-supply-procurement-strategy-2016-20

EVALUATION ADVISORY COMMITTEE CHAIR REPORT

BOARD MEETING **Zulfiqar A. Bhutta**23-24 June 2021, Virtual Meeting





Overview: Evaluations approved under Gavi 4.0

Evaluation		Year				
		2022	2023	2024	2025	
Evaluation of the Cold Chain Equipment Optimisation Platform (CCEOP)	•					
Fragility, Emergencies, Refugees Policy Evaluation	*					
Pneumococcal Vaccine Advance Market Commitment evaluation	*					
Supply and Procurement Strategy review	*					
Private Sector Engagement Approach Evaluation	*					
COVAX Facility and COVAX AMC evaluability, design and baseline evaluation	• •	•				
COVAX Facility and COVAX AMC multi-stage evaluation	•	*		•	•	

Evaluation commissioning period

Evaluation implementation and delivery period

Deliverable that needs to be seen by the EAC

Board meeting 23-24 June 2021

Overview: Gavi 5.0 multi-year evaluation workplan

Evaluation		Year				
		2022	2023	2024	2025	
Evaluation of Gavi's contribution to reaching zero-dose children and missed communities	•		*	*		
Evaluation of Gavi's policy and funding levers	•	•				
Gavi's initial response to COVID-19	•	*				
Gavi 5.0 Mid-term evaluation	•		•			
Gavi's contribution to sustainability of coverage post-transition			*	*		

		Evaluation commissioning period		
		Evaluation implementation and		
		delivery period		
		Deliverable that needs to be seen	i	
	•	by the EAC		

Progress on Evaluations

Evaluation	Progress Update
Evaluation of the Cold Chain Equipment Optimisation Platform (CCEOP)	Draft cross-country report (including Kenya, Guinea, Pakistan, Market Shaping and COVID-19 component) due 30 July 2021 and final report expected early September
Fragility, Emergencies, Refugees Policy Evaluation	Draft report to be shared with EAC focal points for review and quality assurance in June 2021
Pneumococcal Vaccine Advance Market Commitment evaluation	Draft report to be shared with EAC focal points for review and quality assurance in mid-Q3 2021



Progress on Evaluations

Evaluation	Progress Update
Supply and Procurement Strategy review	EAC summary assessment, Evaluation Management Response (EMR) and final report posted on Gavi's website
Private Sector Engagement Approach Evaluation	Recommendation co-creation meeting held in May 2021 Draft report to be shared with EAC focal points for review and quality assurance in June 2021
COVAX Facility and COVAX AMC evaluability, design and baseline evaluation	Service Provider selection – on-going Implementation to commence in July 2021
Gavi's initial response to COVID-19	Drafting of Terms of Reference to share with EAC in June 2021



Additional EAC feedback

- EAC noted with satisfaction the reaffirmation by the Gavi leadership of the importance of the EAC in supporting the independence of Gavi's evaluations, and in guiding mitigation actions in the event of perceived potential risks to evaluation independence
- EAC did express some concerns regarding key shifts in the Evaluation
 Operational Guidelines (EOGs) and provided written comments by consensus
 following the EAC meeting in April as a constructive roadmap for the way
 forward. This feedback will be provided to the incoming Chair for consideration.



Thank you





REVIEW OF DECISIONS

EVALUATION ADVISORY COMMITTEE 14-15 April 2021, virtual meeting



Decision 1: Gavi 5.0 Multi-year Evaluation Workplan

The Gavi Alliance Evaluation Advisory Committee:

Approved Gavi's multi-year (2021–2025) centralised evaluation workplan as set out in Annex B to Doc 04.



Thank you



